Ticker
AERI

Price
15.25
Stock movement up
+- (%)
Company name
Aerie Pharmaceuticals Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
753.62M
Ent value
1.24B
Price/Sales
3.52
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
57.22%
3 year return
-6.07%
5 year return
-23.89%
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

AERI does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF105.15
Price to FCF285.79
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.52
Price to Book-
EV to Sales5.79

FINANCIALS

Per share

Loading...
Per share data
Current share count49.42M
EPS (TTM)-0.76
FCF per share (TTM)0.06

Income statement

Loading...
Income statement data
Revenue (TTM)213.94M
Gross profit (TTM)190.42M
Operating income (TTM)-26.71M
Net income (TTM)-36.55M
EPS (TTM)-0.76
EPS (1y forward)-1.10

Margins

Loading...
Margins data
Gross margin (TTM)89.01%
Operating margin (TTM)-12.49%
Profit margin (TTM)-17.09%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash54.09M
Net receivables73.88M
Total current assets302.81M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets375.59M
Accounts payable9.06M
Short/Current long term debt336.99M
Total current liabilities133.33M
Total liabilities539.57M
Shareholder's equity-163.98M
Net tangible assets-163.98M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)7.17M
Capital expenditures (TTM)4.53M
Free cash flow (TTM)2.64M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-9.73%
Return on Invested Capital-23.82%
Cash Return on Invested Capital1.72%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open15.25
Daily high15.25
Daily low15.25
Daily Volume0K
All-time high73.90
1y analyst estimate15.35
Beta-0.06
EPS (TTM)-0.76
Dividend per share-
Ex-div date-
Next earnings date22 Feb 2023

Downside potential

Loading...
Downside potential data
AERIS&P500
Current price drop from All-time high-79.36%-16.29%
Highest price drop-93.30%-56.47%
Date of highest drop1 Jun 20229 Mar 2009
Avg drop from high-45.85%-11.49%
Avg time to new high27 days13 days
Max time to new high1096 days1805 days
COMPANY DETAILS
AERI (Aerie Pharmaceuticals Inc.) company logo
Marketcap
753.62M
Marketcap category
Small-cap
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
Employees
376
Investor relations
-
SEC filings
CEO
Vicente J. Anido
Country
USA
City
Durham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.
November 24, 2022
Former executives at Aerie Pharmaceuticals are in line for major payouts totaling millions of dollars now that the merger with Alcon is complete.
November 23, 2022
GENEVA, November 22, 2022--Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
November 22, 2022
Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 3, 2022
DURHAM, N.C., November 03, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapie...
November 3, 2022
SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.
October 24, 2022
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
October 21, 2022
We have narrowed our search to five small cap stocks that have provided more than 35% returns year to date,These are: AERI, AMAL, RELL, PHX and SBOW.
October 21, 2022
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
October 21, 2022
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
October 20, 2022
Next page